NM-102 / 9 Meters Biopharma - LARVOL DELTA

9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022 (Issuer Direct) - "9 Meters is collaborating with Gustave Roussy, a leading cancer center in France. Gustave Roussy is expanding on the preclinical research showing that NM-102 was effective when combined with immune checkpoint inhibitors (ICIs) in a mouse model of aggressive skin melanoma, and in combination, improved survival compared to ICIs alone....Preclinical work including testing and formulation development are ongoing to support a potential IND filing in 2023."

IND • Licensing / partnership • Preclinical • Melanoma • Oncology • Skin Cancer • Solid Tumor

9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors (Yahoo Finance) - "9 Meters Biopharma...announced today that the Company has received notice from the United States Patent and Trademark Office (USPTO) that U.S. Patent Application No. 17/239,056 is allowed. The patent demonstrates that NM-102, which can prevent disruption of and/or restore the functional integrity of the ileal and/or colonic intestinal barrier, can improve the benefit of immune checkpoint inhibitors (ICIs) for cancer treatment. Specifically, it demonstrates that NM-102 has utility as an anticancer therapy, specifically in combination with the two major pillars of cancer immunotherapy: anti-PD1 and anti-CTLA4 antibody treatments."

Patent • Oncology